AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
levofolinic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4384 | 80433-71-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A folate analog consisting of the pharmacologically active isomer of LEUCOVORIN.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 30 | mg | O |
| 30 | mg | P |
| 30 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 11.43 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| Vd (Volume of distribution) | 0.27 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 4.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.10 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 100 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MTOR,NTRK1,NTRK2,PDK1,PDK2,PDPK1,PIK3CB,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1 | 58 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,CDK9,DYRK1B,EIF2AK3,EPHB4,GRK2,GRK3,MAP2K6,MAP3K14,MAPK7,PDK1,SIK2,STK33,TEK,TTK | 17 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 7, 2008 | FDA | SPECTRUM PHARMS | |
| Sept. 21, 2018 | PMDA | Pfizer Japan Inc. |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Neutrophil count decreased | 328.29 | 29.99 | 143 | 6900 | 71389 | 90550015 |
| Dermatitis acneiform | 252.99 | 29.99 | 65 | 6978 | 6289 | 90615115 |
| Neutropenia | 206.54 | 29.99 | 157 | 6886 | 224747 | 90396657 |
| Paronychia | 192.34 | 29.99 | 55 | 6988 | 7951 | 90613453 |
| Decreased appetite | 137.19 | 29.99 | 157 | 6886 | 376383 | 90245021 |
| Neuropathy peripheral | 119.71 | 29.99 | 93 | 6950 | 136877 | 90484527 |
| Peripheral sensory neuropathy | 117.58 | 29.99 | 39 | 7004 | 9211 | 90612193 |
| Hyperammonaemia | 105.63 | 29.99 | 33 | 7010 | 6442 | 90614962 |
| Diarrhoea | 105.27 | 29.99 | 227 | 6816 | 938963 | 89682441 |
| Malignant neoplasm progression | 96.47 | 29.99 | 74 | 6969 | 106796 | 90514608 |
| Large intestine perforation | 88.73 | 29.99 | 32 | 7011 | 9680 | 90611724 |
| Myelosuppression | 86.15 | 29.99 | 53 | 6990 | 53538 | 90567866 |
| Mucosal inflammation | 80.14 | 29.99 | 52 | 6991 | 57573 | 90563831 |
| Nausea | 74.45 | 29.99 | 221 | 6822 | 1110095 | 89511309 |
| White blood cell count decreased | 73.33 | 29.99 | 77 | 6966 | 167032 | 90454372 |
| Stomatitis | 70.07 | 29.99 | 96 | 6947 | 274602 | 90346802 |
| Band sensation | 66.79 | 29.99 | 16 | 7027 | 1157 | 90620247 |
| Gastrointestinal perforation | 66.17 | 29.99 | 21 | 7022 | 4311 | 90617093 |
| Drug ineffective | 63.64 | 29.99 | 15 | 7028 | 1384283 | 89237121 |
| Disease progression | 63.12 | 29.99 | 69 | 6974 | 156546 | 90464858 |
| Febrile neutropenia | 62.49 | 29.99 | 69 | 6974 | 158280 | 90463124 |
| Azotaemia | 61.82 | 29.99 | 21 | 7022 | 5327 | 90616077 |
| Hypertensive crisis | 54.68 | 29.99 | 27 | 7016 | 17757 | 90603647 |
| Interstitial lung disease | 54.23 | 29.99 | 46 | 6997 | 76359 | 90545045 |
| Hypomagnesaemia | 54.14 | 29.99 | 34 | 7009 | 35554 | 90585850 |
| Dysentery | 52.63 | 29.99 | 13 | 7030 | 1069 | 90620335 |
| Cholangitis | 52.16 | 29.99 | 20 | 7023 | 7162 | 90614242 |
| Thrombocytopenia | 51.75 | 29.99 | 72 | 6971 | 208653 | 90412751 |
| Diarrhoea haemorrhagic | 51.00 | 29.99 | 22 | 7021 | 10641 | 90610763 |
| Anaemia | 50.80 | 29.99 | 95 | 6948 | 352707 | 90268697 |
| Extrasystoles | 49.28 | 29.99 | 18 | 7025 | 5639 | 90615765 |
| Hypertransaminasaemia | 48.58 | 29.99 | 24 | 7019 | 15801 | 90605603 |
| Cholinergic syndrome | 47.53 | 29.99 | 11 | 7032 | 685 | 90620719 |
| Bone marrow failure | 47.06 | 29.99 | 30 | 7013 | 32191 | 90589213 |
| Posterior reversible encephalopathy syndrome | 46.15 | 29.99 | 26 | 7017 | 22313 | 90599091 |
| Skin disorder | 41.16 | 29.99 | 29 | 7014 | 36677 | 90584727 |
| Palmar-plantar erythrodysaesthesia syndrome | 40.69 | 29.99 | 26 | 7017 | 27997 | 90593407 |
| Pain | 39.77 | 29.99 | 14 | 7029 | 996327 | 89625077 |
| Off label use | 39.21 | 29.99 | 179 | 6864 | 1102073 | 89519331 |
| Metastases to peritoneum | 39.11 | 29.99 | 14 | 7029 | 4141 | 90617263 |
| Platelet count decreased | 38.11 | 29.99 | 50 | 6993 | 136919 | 90484485 |
| Asthenia | 37.15 | 29.99 | 108 | 6935 | 533643 | 90087761 |
| Hyperthermia | 35.71 | 29.99 | 17 | 7026 | 10318 | 90611086 |
| Proteinuria | 34.79 | 29.99 | 22 | 7021 | 23269 | 90598135 |
| Dysgeusia | 31.97 | 29.99 | 29 | 7014 | 52531 | 90568873 |
| Colon cancer | 31.82 | 29.99 | 16 | 7027 | 10928 | 90610476 |
| Leukopenia | 31.53 | 29.99 | 39 | 7004 | 100671 | 90520733 |
| Cutaneous lupus erythematosus | 31.22 | 29.99 | 11 | 7032 | 3107 | 90618297 |
| Dry skin | 30.67 | 29.99 | 36 | 7007 | 88037 | 90533367 |
| Peritonitis | 30.40 | 29.99 | 19 | 7024 | 19686 | 90601718 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Dermatitis acneiform | 464.69 | 27.12 | 142 | 10991 | 7597 | 42602605 |
| Paronychia | 397.08 | 27.12 | 110 | 11023 | 4145 | 42606057 |
| Interstitial lung disease | 314.93 | 27.12 | 216 | 10917 | 78246 | 42531956 |
| Neutrophil count decreased | 272.01 | 27.12 | 182 | 10951 | 63233 | 42546969 |
| Peripheral sensory neuropathy | 221.23 | 27.12 | 84 | 11049 | 8678 | 42601524 |
| Neuropathy peripheral | 217.31 | 27.12 | 193 | 10940 | 101660 | 42508542 |
| Decreased appetite | 194.34 | 27.12 | 245 | 10888 | 192892 | 42417310 |
| Stomatitis | 193.25 | 27.12 | 135 | 10998 | 50194 | 42560008 |
| Neutropenia | 189.67 | 27.12 | 246 | 10887 | 199185 | 42411017 |
| Hypomagnesaemia | 147.12 | 27.12 | 92 | 11041 | 28396 | 42581806 |
| Hyperammonaemia | 141.29 | 27.12 | 59 | 11074 | 7807 | 42602395 |
| Skin disorder | 133.45 | 27.12 | 72 | 11061 | 16872 | 42593330 |
| Nausea | 110.49 | 27.12 | 287 | 10846 | 396512 | 42213690 |
| Drug ineffective | 97.26 | 27.12 | 23 | 11110 | 630174 | 41980028 |
| Diarrhoea | 94.87 | 27.12 | 299 | 10834 | 460550 | 42149652 |
| Gastrointestinal perforation | 85.11 | 27.12 | 35 | 11098 | 4451 | 42605751 |
| Azotaemia | 75.64 | 27.12 | 35 | 11098 | 5909 | 42604293 |
| Palmar-plantar erythrodysaesthesia syndrome | 73.76 | 27.12 | 53 | 11080 | 20529 | 42589673 |
| Leukopenia | 68.82 | 27.12 | 91 | 11042 | 74655 | 42535547 |
| Thrombocytopenia | 63.63 | 27.12 | 148 | 10985 | 190131 | 42420071 |
| Hypersensitivity | 60.38 | 27.12 | 84 | 11049 | 72286 | 42537916 |
| White blood cell count decreased | 58.50 | 27.12 | 104 | 11029 | 110292 | 42499910 |
| Tumour perforation | 55.74 | 27.12 | 15 | 11118 | 504 | 42609698 |
| Anaphylactic shock | 50.82 | 27.12 | 45 | 11088 | 23472 | 42586730 |
| Dysgeusia | 50.40 | 27.12 | 53 | 11080 | 34136 | 42576066 |
| Sciatic nerve palsy | 49.84 | 27.12 | 9 | 11124 | 41 | 42610161 |
| Fixed eruption | 49.47 | 27.12 | 20 | 11113 | 2434 | 42607768 |
| Myelosuppression | 46.38 | 27.12 | 55 | 11078 | 40406 | 42569796 |
| Febrile neutropenia | 44.99 | 27.12 | 128 | 11005 | 185575 | 42424627 |
| Dry skin | 44.69 | 27.12 | 59 | 11074 | 48279 | 42561923 |
| Small intestinal perforation | 42.74 | 27.12 | 19 | 11114 | 2922 | 42607280 |
| Toxicity to various agents | 42.58 | 27.12 | 5 | 11128 | 229131 | 42381071 |
| Malignant neoplasm progression | 42.57 | 27.12 | 90 | 11043 | 108310 | 42501892 |
| Colony stimulating factor therapy | 42.50 | 27.12 | 10 | 11123 | 192 | 42610010 |
| Anaphylactoid reaction | 42.48 | 27.12 | 19 | 11114 | 2964 | 42607238 |
| Metastases to liver | 40.89 | 27.12 | 34 | 11099 | 16292 | 42593910 |
| Hypoalbuminaemia | 40.12 | 27.12 | 33 | 11100 | 15577 | 42594625 |
| Transient aphasia | 39.66 | 27.12 | 12 | 11121 | 617 | 42609585 |
| Pulmonary toxicity | 37.36 | 27.12 | 25 | 11108 | 8630 | 42601572 |
| Colon cancer | 37.14 | 27.12 | 26 | 11107 | 9655 | 42600547 |
| Disease progression | 36.71 | 27.12 | 101 | 11032 | 143555 | 42466647 |
| Erythema | 36.69 | 27.12 | 85 | 11048 | 108708 | 42501494 |
| Folliculitis | 36.58 | 27.12 | 21 | 11112 | 5537 | 42604665 |
| Vomiting | 36.55 | 27.12 | 161 | 10972 | 289562 | 42320640 |
| Enterocolitis | 36.55 | 27.12 | 26 | 11107 | 9903 | 42600299 |
| Malaise | 36.51 | 27.12 | 130 | 11003 | 212026 | 42398176 |
| Hypertransaminasaemia | 35.91 | 27.12 | 25 | 11108 | 9202 | 42601000 |
| Disseminated intravascular coagulation | 35.76 | 27.12 | 38 | 11095 | 24756 | 42585446 |
| Infusion related reaction | 35.72 | 27.12 | 60 | 11073 | 60746 | 42549456 |
| Pulmonary artery thrombosis | 35.67 | 27.12 | 12 | 11121 | 870 | 42609332 |
| Intestinal ischaemia | 35.52 | 27.12 | 25 | 11108 | 9363 | 42600839 |
| Cholinergic syndrome | 34.71 | 27.12 | 11 | 11122 | 660 | 42609542 |
| Bone marrow failure | 34.68 | 27.12 | 43 | 11090 | 33050 | 42577152 |
| Headache | 34.32 | 27.12 | 10 | 11123 | 239359 | 42370843 |
| Chemotherapeutic drug level increased | 33.75 | 27.12 | 9 | 11124 | 292 | 42609910 |
| Arthralgia | 32.46 | 27.12 | 7 | 11126 | 205231 | 42404971 |
| Necrotising fasciitis | 32.13 | 27.12 | 18 | 11115 | 4528 | 42605674 |
| Peritonitis | 31.29 | 27.12 | 31 | 11102 | 18602 | 42591600 |
| Malignant ascites | 31.12 | 27.12 | 10 | 11123 | 628 | 42609574 |
| Duodenal stenosis | 27.65 | 27.12 | 8 | 11125 | 352 | 42609850 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Dermatitis acneiform | 685.38 | 25.24 | 193 | 17838 | 12502 | 110558766 |
| Neutrophil count decreased | 566.12 | 25.24 | 310 | 17721 | 120631 | 110450637 |
| Paronychia | 519.72 | 25.24 | 151 | 17880 | 10930 | 110560338 |
| Neutropenia | 429.36 | 25.24 | 407 | 17624 | 374213 | 110197055 |
| Interstitial lung disease | 383.41 | 25.24 | 254 | 17777 | 139080 | 110432188 |
| Neuropathy peripheral | 363.36 | 25.24 | 271 | 17760 | 179006 | 110392262 |
| Decreased appetite | 311.96 | 25.24 | 385 | 17646 | 475461 | 110095807 |
| Peripheral sensory neuropathy | 307.47 | 25.24 | 112 | 17919 | 16568 | 110554700 |
| Hyperammonaemia | 241.20 | 25.24 | 89 | 17942 | 13643 | 110557625 |
| Diarrhoea | 199.95 | 25.24 | 516 | 17515 | 1138989 | 109432279 |
| Hypomagnesaemia | 180.31 | 25.24 | 116 | 17915 | 60254 | 110511014 |
| Stomatitis | 177.08 | 25.24 | 219 | 17812 | 270023 | 110301245 |
| Skin disorder | 157.41 | 25.24 | 94 | 17937 | 42819 | 110528449 |
| Nausea | 153.86 | 25.24 | 495 | 17536 | 1235195 | 109336073 |
| Azotaemia | 143.30 | 25.24 | 56 | 17975 | 10029 | 110561239 |
| Thrombocytopenia | 137.93 | 25.24 | 222 | 17809 | 348663 | 110222605 |
| Drug ineffective | 136.16 | 25.24 | 40 | 17991 | 1520500 | 109050768 |
| White blood cell count decreased | 132.97 | 25.24 | 175 | 17856 | 229215 | 110342053 |
| Gastrointestinal perforation | 129.72 | 25.24 | 48 | 17983 | 7408 | 110563860 |
| Malignant neoplasm progression | 123.21 | 25.24 | 147 | 17884 | 174420 | 110396848 |
| Febrile neutropenia | 113.63 | 25.24 | 193 | 17838 | 316574 | 110254694 |
| Myelosuppression | 112.29 | 25.24 | 105 | 17926 | 94235 | 110477033 |
| Leukopenia | 111.12 | 25.24 | 129 | 17902 | 148662 | 110422606 |
| Palmar-plantar erythrodysaesthesia syndrome | 108.28 | 25.24 | 73 | 17958 | 40952 | 110530316 |
| Disease progression | 93.22 | 25.24 | 153 | 17878 | 243881 | 110327387 |
| Bone marrow failure | 85.93 | 25.24 | 73 | 17958 | 57775 | 110513493 |
| Large intestine perforation | 84.18 | 25.24 | 45 | 17986 | 16584 | 110554684 |
| Cholinergic syndrome | 79.83 | 25.24 | 22 | 18009 | 1310 | 110569958 |
| Dysgeusia | 79.64 | 25.24 | 76 | 17955 | 69909 | 110501359 |
| Hypertransaminasaemia | 78.34 | 25.24 | 49 | 17982 | 24206 | 110547062 |
| Hypertensive crisis | 75.62 | 25.24 | 48 | 17983 | 24324 | 110546944 |
| Metastases to liver | 74.85 | 25.24 | 55 | 17976 | 35331 | 110535937 |
| Hypoalbuminaemia | 72.75 | 25.24 | 50 | 17981 | 28924 | 110542344 |
| Tumour perforation | 69.57 | 25.24 | 17 | 18014 | 628 | 110570640 |
| Arthralgia | 68.62 | 25.24 | 21 | 18010 | 779611 | 109791657 |
| Colon cancer | 68.14 | 25.24 | 39 | 17992 | 16404 | 110554864 |
| Mucosal inflammation | 67.83 | 25.24 | 81 | 17950 | 96060 | 110475208 |
| Dry skin | 65.19 | 25.24 | 84 | 17947 | 107569 | 110463699 |
| Anaphylactic shock | 64.45 | 25.24 | 59 | 17972 | 51487 | 110519781 |
| Headache | 64.12 | 25.24 | 32 | 17999 | 882345 | 109688923 |
| Pain | 63.09 | 25.24 | 39 | 17992 | 954916 | 109616352 |
| Hyperthermia | 61.31 | 25.24 | 40 | 17991 | 21232 | 110550036 |
| Dysentery | 61.23 | 25.24 | 18 | 18013 | 1353 | 110569915 |
| Platelet count decreased | 59.46 | 25.24 | 122 | 17909 | 230321 | 110340947 |
| Disseminated intravascular coagulation | 59.06 | 25.24 | 51 | 17980 | 41235 | 110530033 |
| Metastases to peritoneum | 58.63 | 25.24 | 25 | 18006 | 5585 | 110565683 |
| Cholangitis | 57.84 | 25.24 | 35 | 17996 | 16300 | 110554968 |
| Band sensation | 56.36 | 25.24 | 16 | 18015 | 1062 | 110570206 |
| Proteinuria | 54.36 | 25.24 | 48 | 17983 | 39970 | 110531298 |
| Small intestinal perforation | 50.75 | 25.24 | 21 | 18010 | 4355 | 110566913 |
| Hyperbilirubinaemia | 50.30 | 25.24 | 41 | 17990 | 30630 | 110540638 |
| Pulmonary artery thrombosis | 50.11 | 25.24 | 16 | 18015 | 1586 | 110569682 |
| Sciatic nerve palsy | 49.20 | 25.24 | 9 | 18022 | 77 | 110571191 |
| Erythema | 48.54 | 25.24 | 130 | 17901 | 291317 | 110279951 |
| Peritonitis | 48.11 | 25.24 | 41 | 17990 | 32566 | 110538702 |
| Fixed eruption | 48.04 | 25.24 | 20 | 18011 | 4212 | 110567056 |
| Toxicity to various agents | 47.90 | 25.24 | 10 | 18021 | 480545 | 110090723 |
| Vomiting | 45.94 | 25.24 | 279 | 17752 | 910396 | 109660872 |
| Enterocolitis | 45.92 | 25.24 | 32 | 17999 | 18917 | 110552351 |
| Anaemia | 44.69 | 25.24 | 192 | 17839 | 546894 | 110024374 |
| Nasopharyngitis | 44.16 | 25.24 | 6 | 18025 | 394355 | 110176913 |
| Ileus | 44.03 | 25.24 | 38 | 17993 | 30691 | 110540577 |
| Malaise | 44.01 | 25.24 | 221 | 17810 | 671598 | 109899670 |
| Transient aphasia | 43.83 | 25.24 | 12 | 18019 | 697 | 110570571 |
| Pyrexia | 42.04 | 25.24 | 270 | 17761 | 897995 | 109673273 |
| Anaphylactoid reaction | 41.81 | 25.24 | 21 | 18010 | 6805 | 110564463 |
| Altered state of consciousness | 41.37 | 25.24 | 49 | 17982 | 57577 | 110513691 |
| Product dose omission issue | 40.95 | 25.24 | 3 | 18028 | 321779 | 110249489 |
| Colony stimulating factor therapy | 40.31 | 25.24 | 11 | 18020 | 631 | 110570637 |
| Depression | 40.26 | 25.24 | 3 | 18028 | 317332 | 110253936 |
| Papilloedema | 40.19 | 25.24 | 21 | 18010 | 7388 | 110563880 |
| Malignant ascites | 39.69 | 25.24 | 13 | 18018 | 1397 | 110569871 |
| Paraesthesia | 38.85 | 25.24 | 116 | 17915 | 276405 | 110294863 |
| Metastases to lung | 38.18 | 25.24 | 31 | 18000 | 23032 | 110548236 |
| Product use in unapproved indication | 37.62 | 25.24 | 13 | 18018 | 447364 | 110123904 |
| Rheumatoid arthritis | 37.54 | 25.24 | 3 | 18028 | 299610 | 110271658 |
| Drug intolerance | 37.46 | 25.24 | 10 | 18021 | 406502 | 110164766 |
| Peripheral swelling | 37.11 | 25.24 | 10 | 18021 | 404024 | 110167244 |
| Intestinal obstruction | 36.14 | 25.24 | 44 | 17987 | 53183 | 110518085 |
| Off label use | 35.73 | 25.24 | 387 | 17644 | 1499798 | 109071470 |
| Ascites | 35.11 | 25.24 | 58 | 17973 | 92750 | 110478518 |
| Necrotising fasciitis | 34.14 | 25.24 | 19 | 18012 | 7572 | 110563696 |
| Weight increased | 33.92 | 25.24 | 13 | 18018 | 419631 | 110151637 |
| Intestinal ischaemia | 33.87 | 25.24 | 25 | 18006 | 16154 | 110555114 |
| Chemotherapeutic drug level increased | 33.04 | 25.24 | 9 | 18022 | 513 | 110570755 |
| Confusional state | 32.49 | 25.24 | 18 | 18013 | 468662 | 110102606 |
| Pain in extremity | 31.94 | 25.24 | 20 | 18011 | 487098 | 110084170 |
| Duodenal stenosis | 31.56 | 25.24 | 10 | 18021 | 967 | 110570301 |
| Dizziness | 31.12 | 25.24 | 41 | 17990 | 698152 | 109873116 |
| Venoocclusive liver disease | 30.72 | 25.24 | 23 | 18008 | 15184 | 110556084 |
| Abdominal discomfort | 30.52 | 25.24 | 13 | 18018 | 393845 | 110177423 |
| Nephrotic syndrome | 30.38 | 25.24 | 22 | 18009 | 13809 | 110557459 |
| Asthma | 30.02 | 25.24 | 3 | 18028 | 250288 | 110320980 |
| Extrasystoles | 29.91 | 25.24 | 18 | 18013 | 8300 | 110562968 |
| Asthenia | 29.68 | 25.24 | 203 | 17828 | 688796 | 109882472 |
| Pulmonary toxicity | 29.68 | 25.24 | 24 | 18007 | 17722 | 110553546 |
| Fall | 29.46 | 25.24 | 33 | 17998 | 603449 | 109967819 |
| Cerebral infarction | 29.12 | 25.24 | 39 | 17992 | 51799 | 110519469 |
| Musculoskeletal stiffness | 27.50 | 25.24 | 6 | 18025 | 279816 | 110291452 |
| Portal hypertension | 26.76 | 25.24 | 17 | 18014 | 8620 | 110562648 |
| Acral peeling skin syndrome | 26.54 | 25.24 | 5 | 18026 | 51 | 110571217 |
| Stoma site haemorrhage | 26.10 | 25.24 | 11 | 18020 | 2387 | 110568881 |
| Hypertension | 26.08 | 25.24 | 157 | 17874 | 509927 | 110061341 |
| Maternal exposure during pregnancy | 26.01 | 25.24 | 5 | 18026 | 254878 | 110316390 |
| Tumour necrosis | 25.93 | 25.24 | 11 | 18020 | 2425 | 110568843 |
| Leukoencephalopathy | 25.79 | 25.24 | 17 | 18014 | 9178 | 110562090 |
| Dermatitis bullous | 25.77 | 25.24 | 22 | 18009 | 17507 | 110553761 |
| Glossodynia | 25.76 | 25.24 | 3 | 18028 | 222001 | 110349267 |
| Hyperhidrosis | 25.74 | 25.24 | 78 | 17953 | 187220 | 110384048 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V03AF04 | VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Detoxifying agents for antineoplastic treatment |
| ATC | V03AF10 | VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Detoxifying agents for antineoplastic treatment |
| FDA CS | M0008658 | Folic Acid |
| FDA EPC | N0000178369 | Folate Analog |
| MeSH PA | D000931 | Antidotes |
| MeSH PA | D020011 | Protective Agents |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
Related Drugs by ATC class:
V03AF Detoxifying agents for antineoplastic treatment 10 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Megaloblastic anemia | indication | 53165003 | DOID:13382 |
| Folic acid deficiency | indication | 190633005 | |
| Malignant tumor of stomach | indication | 363349007 | DOID:10534 |
| Small intestine cancer | indication | 363509000 | DOID:10154 |
| Methotrexate Toxicity | indication | ||
| Adjunct to Fluorouracil Treatment of Colorectal Cancer | indication | ||
| Pyrimethamine Toxicity | indication | ||
| Trimethoprim Toxicity | indication | ||
| Sulfadiazine Toxicity | indication | ||
| Trimetrexate Toxicity | indication | ||
| Bone Marrow Suppression due to Folic Acid Antagonism | indication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.61 | acidic |
| pKa2 | 5.29 | acidic |
| pKa3 | 10.26 | acidic |
| pKa4 | 12.96 | acidic |
| pKa5 | 4.59 | Basic |
| pKa6 | 2.23 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4028507 | VUID |
| N0000182085 | NUI |
| 419573-16-3 | SECONDARY_CAS_RN |
| 68538-85-2 | SECONDARY_CAS_RN |
| 4028507 | VANDF |
| 4028508 | VANDF |
| CHEBI:63606 | CHEBI |
| CHEMBL1908841 | ChEMBL_ID |
| CHEMBL1908361 | ChEMBL_ID |
| CHEMBL3707343 | ChEMBL_ID |
| DB11596 | DRUGBANK_ID |
| 1648126 | RXNORM |
| 132962 | MMSL |
| 21723 | MMSL |
| 25218 | MMSL |
| 35726 | MMSL |
| d05842 | MMSL |
| 005532 | NDDF |
| 005533 | NDDF |
| 395769006 | SNOMEDCT_US |
| 429990006 | SNOMEDCT_US |
| 433468002 | SNOMEDCT_US |
| 782479008 | SNOMEDCT_US |
| C2721771 | UMLSCUI |
| D058766 | MESH_DESCRIPTOR_UI |
| FOZ | PDB_CHEM_ID |
| 135398559 | PUBCHEM_CID |
| WA16A5Y52X | UNII |
| 6883 | INN_ID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Levoleucovorin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9558 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 23 sections |
| LEVOLEUCOVORIN CALCIUM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14335-340 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 24 sections |
| LEVOLEUCOVORIN CALCIUM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14335-341 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 24 sections |
| LEVOLEUCOVORIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-771 | INJECTION, SOLUTION | 175 mg | INTRAVENOUS | ANDA | 25 sections |
| LEVOLEUCOVORIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-773 | INJECTION, SOLUTION | 250 mg | INTRAVENOUS | ANDA | 25 sections |
| Biopar delta-FORTE | HUMAN PRESCRIPTION DRUG LABEL | 6 | 64661-793 | CAPSULE | 2.50 mg | ORAL | unapproved drug other | 11 sections |
| levoleucovorin | Human Prescription Drug Label | 1 | 68083-278 | INJECTION | 10 mg | INTRAVENOUS | ANDA | 23 sections |
| levoleucovorin | Human Prescription Drug Label | 1 | 68083-279 | INJECTION | 10 mg | INTRAVENOUS | ANDA | 23 sections |
| Levoleucovorin Calcium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70121-1572 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 22 sections |
| LEVOLEUCOVORIN CALCIUM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70436-209 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 23 sections |
| LEVOLEUCOVORIN CALCIUM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70436-210 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 23 sections |
| Levoleucovorin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-104 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 24 sections |
| Levoleucovorin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-105 | INJECTION, SOLUTION | 10 mg | INTRAVENOUS | ANDA | 23 sections |